HealthVerity’s Post

The core team of Columbia Data Analytics has been supporting the evidence generation needs of pharmaceutical and biotech clients for 25+ years.    Columbia Data Analytics services include the following: ·      Evidence synthesis: SLRs and NMAs ·      RWE generation: Disease burden, treatment effects, patient journey, comparative effectiveness, HCRU ·      Impact of healthcare policy on cost and outcomes ·      Rare disease and advanced therapies ·      Post marketing studies ·      ECAs ·      Strategic guidance: Economic modeling, AI/ML algorithms, microsimulation   We are data agnostic and have experience across a broad spectrum of data assets and data formats. Below is a list of data sources we currently can access directly: ·      VA: Claims and EMR (linked) ·      DoD/Tricare: Claims and EMR (linked) ·      CMS: Medicare FFS ·      CMS: Medicaid ·      Kythera Labs (open and closed claims - includes identification of 10 largest commercial payers, Medicaid by state (managed care and FFS), Medicare FFS and Medicare Advantage - 5 days current #data #RWE #HCRU #HEOR #ISPOREurope #isporeurope2023 #pharma

🚨 Attention, #digitalhealth professionals: we need your help! 🚨 DiMe is partnering with the Tufts Center for the Study of Drug Development (Tufts CSDD) to model and quantify the net financial impact of the use of #digitalmeasures as endpoints in #clinicaltrials. We have fascinating data that illustrates the benefits of digital endpoints. But we need your help quantifying the costs associated with validating digital measures and implementing those measures as #endpoints in clinical trials. Please take this quick, 15-30 minute survey to capture your important insights on the cost of digital endpoints. There are two versions of the survey, noted below. The data you provide will only be presented in an aggregate and de-identified way. No individual companies or projects will be identified or presented. Complete the survey by August 18 to ensure your insights are included in our field-wide analysis. Fill out the survey here: 📝 For clinical trial sponsors: https://bit.ly/4422KBa 📝 For developers of measures and/or DHTs: https://bit.ly/47eN6Fd Thank you for your help in advancing #digitalmedicine to optimize human health!

Learn how utilizing robust data and analytics platforms, such as TriNetX enables companies like Sanofi to assess patient population and optimize their cohorts for diverse representation. Read the full article: https://ow.ly/x16W30szJmZ Access our diversity resources for better patient outcomes: ow.ly/lOVq30szIq8

Learn how utilizing robust data and analytics platforms, such as TriNetX enables companies like Sanofi to assess patient population and optimize their cohorts for diverse representation. Read the full article: https://ow.ly/XxtP30szIr3 Access our diversity resources for better patient outcomes: ow.ly/lOVq30szIq8

✍ The ONCOVALUE project was highlighted in a recent article by DIA Global Forum - Driving Insights to Action: "Revealing the Future of Healthcare: EU-Funded Projects Revolutionizing Real-World Evidence and Data Analytics" It has become a interesting article. Definitely worth reading! #realworlddata #realworldevidence #health #HorizonEurope #Research

Unlocking the power of patient data for groundbreaking insights! We are excited to share this enlightening blog series on harnessing Real-World Evidence (RWE) in healthcare. Discover why RWE matters and the transformative impact it's creating. Let's dive into the future of data-driven healthcare together. Part 1 is 'Unlocking Important Real World Evidence (RWE) from Patient Data – Why and How?' http://spkl.io/60414cc0f #Healthcare #Data #PatientData #RealWorldEvidence #DataDrivenInsights

By cultivating a trusted online community of expert patients and caregivers, Smart Patients SmartSights ensures rapid cycle patient insights to inform pharma strategy. From digital tech transformation to product planning to HEOR to patient diagnostics. We specialize in agile evidence generation for serious disease areas, providing robust data to meet the demands of a rapidly evolving market and rising expectations. #PatientInsights #PharmaStrategy #HEOR #DigitalTechTransformation #ProductPlanning #AgileEvidenceGeneration

Discover the most comprehensive view of hundreds of millions of patient journeys with the nation’s largest fully interoperable, de-identified healthcare and consumer data ecosystem. HealthVerity Marketplace allows you to build custom patient cohorts based on expansive healthcare criteria, such as diagnosis, drug, procedure, lab test or biomarker. Start discovering today. https://hubs.ly/Q028pmRX0

Harnessing Predictive Analytics for Clinical Trial Efficiency. As we progress further in our series on the role of data in clinical trials, we turn our focus to the burgeoning field of predictive analytics. Harnessing the power of predictive analytics can significantly enhance the efficiency of clinical trials. In this article, we will discuss how predictive analytics can be employed to drive clinical trial efficiency. 1. Patient Recruitment: Predictive analytics can identify potential trial participants, reducing recruitment time and costs. 2. Risk Mitigation: Predictive models can identify potential risks and challenges in a trial, helping to mitigate them proactively. 3. Resource Allocation: By predicting the course of a trial, resources can be optimally allocated to improve efficiency. 4. Adaptive Trials: Predictive analytics can inform adaptive trial designs, allowing for modifications based on interim results. 5. Outcome Forecasting: Predictive models can help estimate trial outcomes, guiding decision-making and strategic planning. Predictive analytics is redefining the way we conduct and manage clinical trials, driving efficiency and innovation. #ClinicalTrials #PredictiveAnalytics #DataScience #PharmaceuticalIndustry #DrugDevelopment

How can SDoH data help Life Sciences companies meet patients where they are? By incorporating SDoH data, #lifesciences companies can move beyond traditional insights gathered solely from claims data and EMRs to truly understand potential barriers and other community and individual factors impacting patient lives. These nuanced #SDoH insights will help to: 1. Address diversity, equity, and inclusion in clinical development and marketing strategies. 2. Develop more effective interventions and programs that can be utilized in parallel to the development and commercialization of treatments. 3. Design healthcare practitioner (HCP) support materials that can aid providers in addressing SDoH within their patient populations. 4. Prioritize subsets of the patient population for optimized patient support and patient engagement programs. 5. Collaborate with customers (e.g., payors, providers) to co-develop initiatives aimed at addressing identified risk factors. 6. Identify challenges impacting patient adherence in order to implement effective mitigation strategies. To learn more, read our whitepaper: How SDoH Data can Enhance Patient Centricity in Life Sciences Research https://hubs.la/Q02zdG860